About US-Taiwan Biomedical Sciences Forum

​

Rapid advancements in gene sequencing, such as reduced costs of Next Generation Sequencing (NGS) and improved big data analysis, have boosted the feasibility and utility of precision medicine. This new medical model uses personalized care, integrated biological data and big data analytics to customize treatments for patients, improve healthcare outcome, and benefit the overall healthcare society. BIS Research reports that the global precision medicine market, valued at USD 43.59 billion in 2016, is projected to reach USD 141.7 billion by 2026 as a result of advancement in gene sequencing and bioinformatics.

​

The success of precision medicine requires interdisciplinary expertise and cross-functional collaboration. Innovations in minimally-invasive technology, AI-enhanced big data, and the use of novel biomarkers have driven the development and evolvement of personalized medicine in the last decade.

​

To gain a full picture of the industry and hear from different perspectives, this forum will feature experts from both academia and industry and across various functional areas in the broader biopharmaceutical value chain. Experts will discuss the emerging trends and challenges in precision medicine, as well as sharing their career takeaway insights to inspire the future leaders in the broader life sciences industry.

​

This forum is hosted by Bay Area Taiwanese Biotechnology Association (BATBA) with the sponsorship from National Science and Technology Council, Taiwan (NSTC).

​

​

About Bay Area Taiwanese Biotechnology Association (BATBA)

​

BATBA is a Founded 501c(3) Non-Profit Organization founded in 2018 and is one of the 10 Taiwanese Biotech Associations in the world. BATBA's mission is to foster career development and networking of the newer Taiwanese generation and to enhance communications and collaborations among the broader biotech sectors in US and Taiwan.